

AWARD NUMBER: W81XWH-14-1-0318

TITLE: Genetic and Diagnostic Biomarker Development in ASD Toddlers Using Resting State Functional MRI

PRINCIPAL INVESTIGATOR: Glahn, David C.

CONTRACTING ORGANIZATION: Yale University
New Haven, CT 06511

REPORT DATE: September 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) September 2015		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 Sep 2014 - 31 Aug 2015	
4. TITLE AND SUBTITLE Genetic and Diagnostic Biomarker Development in ASD Toddlers Using Resting-State Functional MRI				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-14-1-0318	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Glahn, David C. email: david.glahn@yale.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Yale University New Haven, Connecticut 06511-6614				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Our overarching strategy is to exploit three large neuroimaging/neurobehavioral datasets to identify brain-imaging based biomarkers for Autism Spectrum Disorders (ASD). At Yale, we focus on determining if brain networks are influenced by genetic factors and if these genetic factors also influence other traits associated with ASD. Specifically, we will provide heritability estimates and test for pleiotropy between putative ASD functional and structural networks and cognitive and behavioral traits. To demonstrate the feasibility of this analytic approach, we conducted an initial analysis with over 250 seed regions simultaneously to provide measures of brain connectivity within 14 previously derived functional networks. Next, we estimated heritability for these structural and functional networks, examined the co-heritability between different modalities (e.g. function and structure) and searched the genome for chromosomal loci influencing these networks. We demonstrated that many of these intrinsic brain networks are heritable, that different genetic factors influence brain function and structure and localized a number of chromosomal regions that harbor genes influencing brain connectivity. These findings, which were presented at the annual meeting of the Organization for Human Brain Mapping, clearly demonstrate our ability to conduct similar analyses with ASD specific networks, once these are identified in the BrainMap and ACE datasets.					
15. SUBJECT TERMS Autism spectrum disorder (ASD); biomarker; early brain development; intrinsic functional brain networks; functional MRI (fMRI); clinical outcome; genomic; heritability; genetic control; pleiotropy					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 10	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (Include area code)

TABLE OF CONTENTS

	Page
1. Introduction.....	2
2. Keywords.....	2
3. Accomplishments.....	2
4. Impact.....	5
5. Changes/Problems.....	6
6. Products.....	6
7. Participants and Other Collaborating Organizations.....	6
8. Special Reporting Requirements.....	7
9. Appendices.....	7

1. INTRODUCTION

Our strategy is to exploit three large neuroimaging/neurobehavioral datasets in order to identify brain-imaging based biomarkers for Autism Spectrum Disorders (ASD), including 1) BrainMap, developed and maintained by Peter Fox at the University of Texas Health Science Center at San Antonio (UTHSCSA); 2) the Autism Center of Excellence (ACE) neuroimaging archive, developed and maintained by Eric Courchesne at the University of California at San Diego (UCSD); and 3) the Genetics of Brain Structure (GOBS) neuroimaging genetics archive, developed and maintained by David Glahn at Yale University. To develop ASD biomarkers, we aim to (1) develop multi-regional functional-connectivity models of networks implicated in ASD by iterative and hierarchical meta-analyses of the BrainMap database; (2) test the ability of the neural-system functional-connectivity models to differentiate between ASD and TYP children in a cohort previously acquired ACE cohort; and assess the heritability and pleiotropy of these functional networks, in a previously imaged and previously genotyped cohort of families with extended pedigrees. At Yale, we focus on the final aim, estimating heritability of putative ASD networks and testing for pleiotropy between these networks and cognitive and behavioral measures.

2. KEYWORDS

Autism spectrum disorder (ASD); biomarker; early brain development; intrinsic functional brain networks; functional MRI (fMRI); clinical outcome; genomic; heritability; genetic control; pleiotropy

3. ACCOMPLISHMENTS

a. What were the major goals of the Yale site?

At the Yale site, we focus on estimating heritability of putative ASD functional and structural networks, testing for pleiotropy between these networks and cognitive and behavioral measures and training post-doctoral associates and others to conduct the needed analyses. Below we outline the major tasks identified in the original Scope of Work (SOW) relevant for this reporting period.

Administrative Tasks (Prior to Aims)

Major Task 1 *was to submit and obtain ethics approval from our local ethical review board. We accomplished this goal (Milestone #1) ahead of schedule: Yale's Human Research Protection Program board approved the project on April 15, 2014 (HIC 1403013622).*

Major Task 2 *was to advertise, interview, hire and train staff dedicated for the project. After several rounds of interviews and advertising in national and international scientific meetings, we offered a post-doctoral fellowship to Dr. Karen Hodgson (see section 7.*


Participants, below). Dr. Hodgson accepted the offer and joined our group in February of 2015. She is currently classified as a Postdoctoral Associate at Yale University, Department of Psychiatry, who is dedicated to this project at 60% effort. Dr. Hodgson has undergone an extensive training program and has mastered the methods necessary for the genetic analyses to be conducted for this project (Milestone #2).

Tasks In support of Specific Aim 3 (Yale University Site)

Major Task 1 *involved the pre-processing of structural and functional data for subjects from the GOBS cohort. Pre-processing involved a number of quality control and analytic steps. Quality control, preprocessing and neuroanatomic parcellation were performed on ~1200 scans from individuals in randomly ascertained extended pedigrees by April/May of 2015 (Subtask 1). In total, 997 images were found to be of adequate quality and were reliably parcellated using FreeSurfer 5.1. Similarly, quality control,*

preprocessing and functional parcellation was conducted on ~850 scans from individuals in randomly ascertained extended pedigrees by May of 2015 (Subtask 2). In total, 783 images were found to be of adequate quality and were reliably parcellated into functional networks using ICA tools. Thus, Milestone #1 was accomplished for the GOBS cohort by May of 2015.

Figure 1. Example Functional Connectivity Networks based upon methods by Power et al (2013)



Major Task 2 involved conducting intrinsic connectivity analyses from functional networks derived from the BrainMap and ACE datasets. Two “agnostic” intrinsic connectivity analyses were conducted by August of 2015. The first, utilized an extension of the methods initially published by Power and colleagues (Power JD, Schlaggar BL, Lessov-Schlaggar CN, Petersen SE. Evidence for hubs in human functional brain networks. *Neuron*. 2013 Aug 21;79(4):798-813. PMID: 23972601). This approach uses over 250 seed regions simultaneously to provide regional and network-level measures of brain connectivity. Using this analytic approach, we estimated heritability for a set of structural and functional networks, examined the co-heritability between these different modalities and searched the genome for chromosomal loci influencing these networks. In **Figure 1**, we provide examples of two of the 14 derived networks, based on the network configuration determined in the Power et al., work. For our current experiment, we defined network connections as either short or long (greater or less than 40mm). In **Figure 2**, we indicate the number and chromosomal locations of loci that influenced network-based connectivity measures found to be significantly heritable. Findings from these analyses were presented at the 21st annual meeting of the Organization for Human Brain Mapping in Honolulu, HI, entitled “Shared and Unique Genetic Influences on Structural and Functional Connectivity.”


The second analytic approach involved the application of surface based analytic techniques developed by the Human Connectome Project (<http://www.humanconnectome.org>), a NIH roadmap initiative designed to map normal variation in brain connectivity. This computationally demanding analytic strategy derives dense connectivity maps for each subject based upon a surfaced-

based parcellation and then combined these connectivity maps using a combined function-structure alignment strategy. This method provides similar heritability estimates as those derived using the Power et al method.

These analyses fulfill Milestone #2.

Once we receive the functional networks derived from BrainMap (Specific Aim 1) and the ACE cohort (Specific Aim 2), we will conduct similar analyses with these data.

Figure 2. Linkage-Manhattan Plot for Structural and Functional Connectivity Analyses



b. What was accomplished under these goals at the Yale University site?

All of the work described above was conducted at the Yale site. In addition, a conceptually similar analyses was conducted using neuroanatomic networks disrupted in schizophrenia. Specifically, we used source-based morphometry, a multivariate technique optimized for structural MRI, in a large sample of randomly ascertained pedigrees ($N = 887$) to derive an insula-medial prefrontal cortex (mPFC) component and to investigate its genetic determinants. First, we replicated the insula-mPFC grey matter component as an independent source of grey matter variation in the general population, and verified its relevance to schizophrenia in an independent case-control sample. Secondly, we showed that the neuroanatomical variation defined by this component is largely determined by additive genetic variation ($h^2 = 0.59$), and genome-wide linkage analysis resulted in a significant linkage peak at 12q24 ($LOD = 3.76$). This region has been of significant interest to psychiatric genetics as it contains the Darier's disease locus and other proposed susceptibility genes (e.g. *DAO*, *NOS1*), and it has been linked to affective disorders and schizophrenia in multiple populations. Thus, in conjunction with previous clinical studies, our data imply that one or more psychiatric risk variants at 12q24 are co-inherited with reductions in mPFC and insula grey matter concentration. The results of these analyses were reported in a manuscript recently accepted for publication in a peer-reviewed journal. This article is currently in press at the

American Journal of Medical Genetics, Part B Neuropsychiatric Genetics. The success of this similar project speaks to the feasibility and potential for success of the ASD project.

c. What opportunities for training and professional development has the project provided at the Yale University site?

Although Dr. Karen Hodgson joined the team with considerable molecular genetics experience, she did not have formal training in quantitative or statistical genetics. Thus, in order for Dr. Hodgson to perform the analyses needed for the current project, she learned a new skill set involving the use of complex analytic methods in the service of furthering our understanding of human brain connectivity in general and how connectivity is disrupted in ASD.

d. How were the results disseminated to communities of interest?

Although we have presented preliminary analyses at the 2015 annual meeting for the Organization for Human Brain Mapping, we have not conducted the key analyses designed to identify biomarkers for ASD. Thus, we have nothing to report as of yet.

e. What do you plan to do during the next reporting period to accomplish the goals?

In the coming months we anticipate receiving the final set of the initial intrinsic network results in the Autism Spectrum Disorder sample from Dr. Courchesne. We additionally expect to receive analysis from Dr. Courchesne comparing and contrasting his initial ASD intrinsic network results from Dr. Fox's multi-stage MACM analyses. We intend to utilize these results in addition to the findings described above from the Yale site to use resting-state connectivity alterations and behavioral characterizations of ASD as quantitative traits, computing heritability and pleiotropy estimates.

4. IMACT

a. What is the impact on understanding ASD brain development of the project?

As outlined above, we have a number of preliminary results that are directly relevant to the proposed project, further demonstrate the plausibility of the proposed analyses and improve our understanding of the neurogenetics of human brain connectivity. However, as described above, the exact functional and structural connectivity models that typify ASD have yet to be created (e.g. Aims 1 & 2) and, thus, we have yet to estimate their genetic effects.

b. What was the impact of the project results on other disciplines, technology transfer, or society beyond science and technology?

Other Disciplines: Neurogenetics. Thus far, our project has estimated the genetic control over functional and structural connectivity measures, documented that independent genetic factors appear to influence these traits, and localized chromosomal loci influencing either functional, structural or both structural and functional connectivity. These results will be directly relevant for ASD when the exact networks (biomarkers) associated with ASD are identified.

Technology Transfer: Our initial findings were reported in an international scientific meeting in May 2015. The article documenting these findings is in development and will be submitted to a peer-review journal for publication in the fall.

Society: Nothing to Report

5. CHANGES/PROBLEMS

No scientific, design, or experiment problems have occurred and thus no significant changes to the project are proposed. As described above, we completed pre-processing of functional and structural connectivity measures using the originally proposed methods. However, newer surface-based methods developed by the Human Connectome Project have become available to the scientific community. Thus, we have implemented these methods as well and will conduct all analyses in parallel.

6. PRODUCTS

The products resulting from the project during the reporting period include the following conference paper:

- Glahn et al., "Shared and Unique Genetic Influences on Structural and Functional Connectivity," 21st annual meeting of the Organization for Human Brain Mapping, Honolulu, HI

7. PARTICIPANTS AND OTHER COLLABORATING ORGANIZATIONS

a. What individuals have worked on the project?

Work on this project has been limited to David C Glahn, PhD, the PD/PI, and Dr. Karen Hodgson, post-doctoral associate.

David C. Glahn, Ph.D. (0.6 calendar months), years 1-2. Partnering Principal Investigator is an expert in the application of neurocognitive and neuroimaging phenotypes in large-scale behavioral and molecular genetic studies of psychiatric illnesses. He is a Professor in the Department of Psychiatry, Yale University School of Medicine, and an Olin Neuropsychiatric Research Center Scholar where he directs the Imaging Genomics laboratory. As outlined in the Scope of Work, Dr. Glahn has ultimate responsibility for conducting neurocognitive, neuroimaging and behavioral genetic analyses in support of Specific Aim 3.

Karen Hodgson (7.2 calendar months, or 60% effort), years 1-2. Under the supervision of Dr. Glahn, this Dr. Hodgson has conduct neurocognitive, neuroimaging and behavioral genetic analyses in support of Specific Aim 3. In addition, she liaisons with other investigators involved in the project.

b. Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to Report

c. What other organizations were involved as partners?

As per the original application, the other organizations involved as partners are the University of Texas Health Science Center San Antonio (Dr. Fox, the overall project P.I.) and the University of California San Diego site (Dr. Courchesne, P.I. at that site).

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARD: This project is part of a Collaborative Award and this Progress Report is from the Yale University site (Glahn). Comparable progress reports from Dr. Peter Fox at the University of Texas Health Science Center San Antonio and Dr. Eric Courchesne at University of California San Diego will be submitted separately.

9. APPENDICES

Attached is the published abstract for Glahn et al., "Shared and Unique Genetic Influences on Structural and Functional Connectivity," 21st annual meeting of the Organization for Human Brain Mapping, Honolulu, HI

Glahn et al., "Shared and Unique Genetic Influences on Structural and Functional Connectivity," 21st annual meeting of the Organization for Human Brain Mapping, Honolulu, HI

Abstract: The relationship between in vivo measures of structural connectivity, often indexed with diffusion-weighted imaging, and functional connectivity, typically measured with resting-state functional MRI, appears to be complex. While structural connections appear to facilitate some aspects of functional connectivity, functional relationship may include multiple structural pathways. However, most systems neuroscience models of brain connectivity suggest that anatomical and physiological processes are dependent, in part, upon common neurobiological mechanisms. While there is growing evidence that measures of functional and structural connectivity are influenced by genetic factors, little is known about potential pleiotropy (e.g. the same genes influencing both structural and functional connectivity). Using 1606 individuals from extended pedigrees with both resting-state and diffusion weighted scans, we (1) establish the heritability of structural and functional connectivity in previously defined brain networks, (2) use genetic correlations to show statistical evidence that common genes influence both types of measures, and (3) show that specific chromosomal loci influence both structural and functional connectivity.